Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 5
2020 2
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Miyake M, Hori S, Ohnishi S, Toritsuka M, Fujii T, Shimizu T, Owari T, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K. Miyake M, et al. Cancer Sci. 2019 Oct;110(10):3315-3327. doi: 10.1111/cas.14158. Epub 2019 Aug 19. Cancer Sci. 2019. PMID: 31385407 Free PMC article.
Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
Miyamoto T, Miyake M, Toyoshima Y, Fujii T, Shimada K, Nishimura N, Iida K, Nakahama T, Hori S, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Ohbayashi C, Fujimoto K. Miyamoto T, et al. Int J Urol. 2021 Jul;28(7):720-726. doi: 10.1111/iju.14545. Epub 2021 Mar 18. Int J Urol. 2021. PMID: 33734503
Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
Miyamoto T, Miyake M, Nakahama T, Nishimura N, Onishi K, Iida K, Yonemori M, Enokida H, Nakagawa M, Matsumoto H, Matsuyama H, Matsushita Y, Miyake H, Fujii T, Shimada K, Baba S, Kinjyo M, Shimokama T, Okumura K, Fujimoto K; Nishinihon Uro-oncology Extensive Collaboration group. Miyamoto T, et al. Int J Urol. 2023 May;30(5):473-481. doi: 10.1111/iju.15162. Epub 2023 Feb 14. Int J Urol. 2023. PMID: 36788781
Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapy.
Miyake M, Owari T, Iwamoto T, Morizawa Y, Hori S, Marugami N, Shimada K, Iida K, Ohnishi K, Gotoh D, Tatsumi Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Yoneda T, Tanaka N, Fujimoto K. Miyake M, et al. Support Care Cancer. 2018 Apr;26(4):1077-1086. doi: 10.1007/s00520-017-3924-0. Epub 2017 Oct 11. Support Care Cancer. 2018. PMID: 29022158
A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future 'MRI-PDD Fusion TURBT'.
Miyake M, Maesaka F, Marugami N, Miyamoto T, Nakai Y, Ohnishi S, Gotoh D, Owari T, Hori S, Morizawa Y, Itami Y, Inoue T, Anai S, Torimoto K, Fujii T, Shimada K, Tanaka N, Fujimoto K. Miyake M, et al. Diagnostics (Basel). 2019 Sep 4;9(3):112. doi: 10.3390/diagnostics9030112. Diagnostics (Basel). 2019. PMID: 31487881 Free PMC article.
11 results